• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 4. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 5. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636

Comprehensive Overview of (4-Isopropyl-piperazin-1-yl)-acetic acid (CAS No. 95470-68-1)

(4-Isopropyl-piperazin-1-yl)-acetic acid (CAS No. 95470-68-1) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various therapeutic applications. This comprehensive overview aims to provide an in-depth understanding of the chemical properties, biological activities, and recent advancements in the research and development of (4-Isopropyl-piperazin-1-yl)-acetic acid.

Chemical Structure and Properties: (4-Isopropyl-piperazin-1-yl)-acetic acid is a derivative of piperazine, a six-membered heterocyclic amine with two nitrogen atoms. The presence of an isopropyl group and an acetic acid moiety imparts distinct chemical and physical properties to this compound. The molecular formula of (4-Isopropyl-piperazin-1-yl)-acetic acid is C₉H₁₇N₂O₂, with a molecular weight of approximately 183.24 g/mol. It is a white crystalline solid at room temperature and is soluble in water and organic solvents such as ethanol and dimethyl sulfoxide (DMSO).

Synthesis: The synthesis of (4-Isopropyl-piperazin-1-yl)-acetic acid can be achieved through various routes, including the reaction of 4-isopropylpiperazine with chloroacetic acid or acetyl chloride followed by hydrolysis. One common method involves the nucleophilic substitution of 4-isopropylpiperazine with chloroacetic acid in the presence of a base such as sodium hydroxide or potassium carbonate. This reaction yields the desired product with high purity and yield.

Biological Activities: Recent studies have highlighted the diverse biological activities of (4-Isopropyl-piperazin-1-yl)-acetic acid. One of its notable properties is its ability to modulate neurotransmitter systems, particularly serotonin (5-HT) and dopamine (DA) receptors. Research has shown that this compound can act as a partial agonist or antagonist at these receptors, making it a potential candidate for the treatment of neurological disorders such as depression, anxiety, and schizophrenia.

In addition to its receptor-modulating properties, (4-Isopropyl-piperazin-1-yl)-acetic acid has been investigated for its anti-inflammatory effects. Studies have demonstrated that it can inhibit the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) in vitro and in vivo models. These findings suggest that this compound may have therapeutic potential in inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

Clinical Applications: The therapeutic potential of (4-Isopropyl-piperazin-1-yl)-acetic acid has been explored in preclinical studies, with promising results. In animal models of depression, administration of this compound has been shown to improve behavioral outcomes and reduce depressive-like symptoms. Similarly, in models of anxiety, it has exhibited anxiolytic effects without causing significant side effects.

Clinical trials are currently underway to evaluate the safety and efficacy of (4-Isopropyl-piperazin-1-yl)-acetic acid in human subjects. Preliminary data from phase I trials have indicated that the compound is well-tolerated at various dose levels, with no serious adverse events reported. Further studies are needed to fully assess its therapeutic potential and determine optimal dosing regimens.

Mechanisms of Action: The mechanisms underlying the biological activities of (4-Isopropyl-piperazin-1-yl)-acetic acid

Future Directions: The ongoing research on (4-Isopropyl-piperazin-1-yl)-acetic acid

In conclusion, (4-Isopropyl-piperazin-1-yl)-acetic acid

• 37478-58-3(2-(piperazin-1-yl)acetic acid)
• 5430-78-4(2-4-(carboxymethyl)piperazin-1-ylacetic Acid)
• 87980-97-0(4-(2-aminoethyl)-1-Piperazineacetic acid)
• 54699-92-2(2-(4-methylpiperazin-1-yl)acetic acid)
• 44976-83-2(2-(Diisopropylamino)acetic acid)
• 672285-91-5((4-ethyl-1-piperazinyl)acetic Acid)
• 124335-65-5(4-(2-Hydroxyethyl)-piperazin-1-yl-acetic Acid)
• 137881-21-1(1,4,7,10,13-Pentaazabicyclo[11.2.2]heptadecane-4,7,10-triacetic acid)
• 5394-32-1(2-[carboxymethyl(propan-2-yl)amino]acetic Acid)
• 108957-96-6(N-Isopropyl-N-methylglycine)